The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications

Amir Hossein Miri, Mojtaba Kamankesh, Antoni Llopis-Lorente, Chenguang Liu, Matthias G. Wacker, Ismaeil Haririan, Hamid Asadzadeh Aghdaei, Michael R. Hamblin, Abbas Yadegar, Mazda Rad-Malekshahi, Mohammad Reza Zali

Research output: Contribution to journalReview articlepeer-review

7 Citations (Scopus)

Abstract

Helicobacter pylori (H. pylori) is a notorious, recalcitrant and silent germ, which can cause a variety of debilitating stomach diseases, including gastric and duodenal ulcers and gastric cancer. This microbe predominantly colonizes the mucosal layer of the human stomach and survives in the inhospitable gastric microenvironment, by adapting to this hostile milieu. In this review, we first discuss H. pylori colonization and invasion. Thereafter, we provide a survey of current curative options based on polypharmacy, looking at pharmacokinetics, pharmacodynamics and pharmaceutical microbiology concepts, in the battle against H. pylori infection.

Original languageEnglish
Article number917184
JournalFrontiers in Pharmacology
Volume13
DOIs
Publication statusPublished - 27 Jun 2022

Keywords

  • H. pylori
  • antibiotic therapy
  • biopharmaceutical principles
  • pharmaceutical microbiology
  • pharmacodynamics
  • pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'The Potential Use of Antibiotics Against Helicobacter pylori Infection: Biopharmaceutical Implications'. Together they form a unique fingerprint.

Cite this